Introduction/Background Endometrial cancer (EC) is the most common gynaecological cancer. Its incidence has been rising over the years with aging and increased obesity of the high-income countries’ populations. Metabolic syndrome (MetS) has been suggested to be associated with EC. The aim of this study was to assess whether MetS has a significant impact on oncological outcome in EC patients.

Methodology This retrospective study included a total of 408 patients treated for EC between January 2010 and December 2020 in two referral oncological centers. Obesity (body mass index > 30 kg/m2), arterial hypertension (AH) and diabetes mellitus (DM) were criteria for the identification of MetS. The impact of MetS on progression free survival (PFS) and overall survival (OS) was assessed with log-rank test and Cox regression analysis.

Results The median age was 64 years and 37 patients (9.1%) fulfilled the criteria for MetS. The median follow-up time was 43 months.

Patients suffering from MetS did not show any significant differences regarding PFS (36.0 vs. 40.0 months, HR: 1.49, 95% CI 0.792–2.801, p=0.21) and OS (38.0 vs. 43.0 months, HR: 1.66, 95% CI 0.965–2.869, p=0.63) compared to patients without MetS.

Patients with obesity alone had a significantly shorter median PFS compared to non-obese cohort (34.5 vs. 44.0 months, p=0.03). AH and DM separately had no significant impact on PFS (p>0.05) and OS (p>0.05).

Conclusion In current analysis MetS in patients with EC was not associated with worse oncological outcome. However, obesity remains an important comorbidity associated with worse PFS.

Disclosures no